Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Fibromyalgia syndrome (FMS) is a chronic condition with unknown aetiology. The pathophysiology of the disease is incompletely understood; despite advances in our knowledge with regards to abnormal central and peripheral pain processing, and hypothalamo–pituitary–adrenal dysfunction, there is no clear specific pathophysiological therapeutic target. The management of this complex condition has thus perplexed the medical community for many years, and several national and international guidelines have aimed to address this complexity. The most recent guidelines from European League Against Rheumatism (EULAR) (2016), Canadian Pain Society (2012), and The Association of the Scientific Medical Societies in Germany (AWMF) (2012) highlight the change in attitudes regarding the overall approach to FMS, but offer varying advice with regards to the use of pharmacological agents. Amitriptyline, Pregabalin and Duloxetine are used most commonly in FMS and though modestly effective, are useful adjunctive treatment to non-pharmaceutical measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952 · cited 1×
“In 2010, these criteria were updated to change the focus towards a subjective widespread body pain index (WPI) and symptom severity scale (SS), taking into account cognitive symptoms, sleep, fatigue and additional somatic symptoms [4].”
BackgroundPsychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“The endogenous cannabinoids and their receptors have been localized to multiple levels of nervous system (both peripheral and central) [42], and have an acknowledged role in helping to regulate neural process associated with pain perceptions, mood, appetite and memory [43].”
BackgroundEULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Self-citationArnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“2004 [88] Randomised double-blind, placebo controlled trial (n = 207).”
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 2×
“However, DLX 20–30 mg/day has not shown to be effective, and no difference was found between 60 mg/day compared to 120 mg/day [22].”
BackgroundArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“2005 [89] Randomised double-blind placebo controlled trial.”
Fitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
Bennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Cited by
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update
Siracusa, R., Paola, R. D., Cuzzocrea, S., & Impellizzeri, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083891 · Cited by 659
Associations between chronic pain, anxiety, and depression among adults in the United States
Mullins, P. M., Yong, R. J., & Bhattacharyya, N. (2023) · Pain Practice · doi:10.1111/papr.13220 · Cited by 98
“Furthermore, clinical guidelines for several chronic pain conditions list antidepressants as first- line recommended therapies.(32,33) Additionally, nonpharmaceutical treatments such as cognitive behavioral therapy and acceptance and commitment therapy may be effective in the treatment of depression, anxiety, and chro…”
BackgroundSingh, L., Kaur, A., Bhatti, M. S., & Bhatti, R. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02805-5 · Cited by 55
Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis
Migliorini, F., Maffulli, N., Eschweiler, J., Baroncini, A., Bell, A., & Colarossi, G. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03995-z · Cited by 40
Montero-Marin, J., Van Gordon, W., Shonin, E., Navarro-Gil, M., Gasión, V., López-del-Hoyo, Y., Luciano, J. V., & Garcia-Campayo, J. (2020) · Mindfulness · doi:10.1007/s12671-019-01302-8 · Cited by 22
“In the absence of a single goldstandard treatment, some guidelines propose first-line pharmacological treatments for FM using antidepressants such as amitriptyline, duloxetine, or milnacipran (Häuser et al. 2008; Kia and Choy 2017; Macfarlane et al. 2017).”
Background
Metadata
- Authors
- Kia, S., & Choy, E.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2017-05-08
- Volume
- 5
- Issue
- 2
- Pages
- 20
- ISSN
- 2227-9059 (ISSN-L)
- OpenAlex
- W2612014884
- Cited by
- 151
- References
- 24
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. https://app.cochat.ai/papers/10.3390/biomedicines5020020
- The paper
- Kia, S., & Choy, E. (2017). Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines. https://doi.org/10.3390/biomedicines5020020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.